Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track

Cartesian Therapeutics, Inc.

2025-Q3 EPS reported -$1.45 revenue$1,850,000

Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.
Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.
Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.
R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.